Following a spate of large-scale pharma investments in the U.S. last year, German conglomerate Bayer is advancing its own plans to expand in America, in a move the company is framing as the ...
Eli Lilly’s Jaypirca, the first noncovalent BTK inhibitor, has won FDA approval for the first-line treatment of chronic ...
Already sharing the load on two biosimilar assets, Teva Pharmaceutical and Samsung Bioepis have elected to take their ...
In three deals each worth $2 billion or more, AstraZeneca is investing in Summit Therapeutics with a focus on ivonescimab and ...
While Foundayo’s insulin-matching potential in type 2 diabetes had been established in a topline readout earlier this year, ...
Genentech is turning up the volume on breast cancer conversations in its “About Damn Time” campaign with Breastcancer.org and ...
With GLP-1s paving the way, a consumer shift is happening across markets for certain branded pharmaceuticals. | With GLP-1s ...
In Milan this week, Novo and Eli Lilly took the stage at the European Association for the Study of Diabetes 2026 meeting with ...
Eli Lilly’s portfolio of weight loss and diabetes medications have become a dominant force in the market—but access to the ...
Real Chemistry has created an artificial intelligence-enabled platform to improve a manual, fragmented stage of the ...
Taiho Pharmaceuticals, together with U.S.-based subsidiary Taiho Oncology, has inched closer to approval of another oral ...
INS is Gazyva’s second immune-mediated indication, following an approval last October in adult lupus nephritis, a potentially ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results